Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex Inc (NASDAQ: GNPX) is a clinical-stage biotechnology company pioneering gene therapies for cancer and diabetes through its non-viral Oncoprex Delivery System. This dedicated news hub provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access essential updates including Reqorsa Gene Therapy trial progress, FDA designations for lung cancer treatments, and advancements in diabetes program GPX-002. Our curated collection features press releases on scientific collaborations, financial disclosures, and therapeutic innovation breakthroughs.
Key focus areas include tumor suppressor gene research, combination therapy trials, and novel approaches to pancreatic cell transformation. Bookmark this page for verified updates about Genprex's pipeline developments and industry recognition in the oncology and diabetes therapeutic spaces.
Genprex, a clinical-stage gene therapy company, announced the passing of its co-founder and CEO, Rodney Varner, due to complications from cancer. Ryan Confer has been appointed as the new President and CEO. Under Varner's leadership, the company achieved significant milestones in developing therapies for cancer and diabetes. The company expresses its condolences to Varner's family and colleagues.
Genprex, Inc. (
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
